Parc Scientifique de Luminy
IBDML, Case 907
Pharmaxon SA
Pharmaxon aims to control cell mobility to fight disorders of the central nervous system and cancer. For glioblastoma, it has developed a neural cell mobility inhibitor that blocks cell migration in vitro and limits glioblastoma proliferation in animal models.
More from Archive
More from Scrip
• By
The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.
• By
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
• By
Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.